Objective-Increased von Willebrand factor (VWF) levels in lungs are associated with diseases such as pulmonary hypertension. The objective of our study was to determine the mechanism of increased VWF levels in conditions, such as hypoxia, which contribute to pulmonary hypertension. Approach and Results-We have previously reported generation of transgenic mice that express LacZ transgene under the regulation of lung-and brain-specific transcriptional regulatory elements of the VWF gene. Hypoxia exposure of these transgenic mice resulted in increased VWF and LacZ mRNA levels as well as redistribution of their expression from primarily larger vessels in the lungs to microvessels. Exposure of cultured lung microvascular endothelial cells to hypoxia demonstrated that VWF upregulation was accompanied by increased platelet binding. Transcription upregulation was mediated through inhibition of the repressor nuclear factor-IB association with the VWF promoter, and increased nuclear translocation of the transcription factor YY1 and association with its cognate binding site on the VWF gene. Knockdown of YY1 expression abolished the hypoxia-induced upregulation and reduced basal level of VWF. Conclusions-These analyses demonstrate that hypoxia induces a phenotypic shift, accompanied by modulation of nuclear factor-IB and YY1 activities, in microvascular endothelial cells of the lungs to support VWF promoter activation. Vasc Biol. 2013;33:1329-1338 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
V on Willebrand factor (VWF) is a glycosylated protein that is expressed exclusively in endothelial cells and megakaryocytes. This highly restricted expression pattern is used to distinguish endothelial cells from other cell types. 1 However, VWF is not uniformly, or in similar levels, expressed by endothelial cells of all vascular beds. 2, 3 In lungs, although VWF is highly abundant and uniformly expressed in vessels of diameters ≥40 µm, expressions in capillaries and microvessels are low and display a mosaic pattern. [4] [5] [6] [7] Both low and high levels of VWF lead to diseases. [8] [9] [10] [11] [12] [13] Qualitative and quantitative deficiencies of VWF lead to the most common inherited bleeding disorder: von Willebrand disease. 13 Conversely, excessive circulating levels of VWF are an independent risk factor for cardiovascular mortality. 14 Increased VWF expression specifically in lungs is associated with acute lung injury, which has a degree of pulmonary hypertension (PH) among its characteristics. [15] [16] [17] [18] [19] [20] [21] Pathophysiological changes in pulmonary vasculature that are associated with acute lung injury include endothelial dysfunction as well as vascular remodeling and increased vascular tone, which consequently alters the production of endothelial-derived molecules, leading to an imbalance of factors that regulate vascular tone as well as initiation of inflammation, coagulation, and thrombogenicity. 15 A prothrombotic state is favored with increased production of procoagulant molecules, such as VWF. Despite well-established association of increased VWF with PH, its mechanism has not been determined. Increased VWF in circulating plasma may result from the release of VWF protein from storage organelles (Weibel-Palade bodies), 22 and regulation of VWF gene expression at various levels, including posttranscriptional or transcriptional activity.
In vitro and in vivo analyses of the mechanism of transcriptional regulation of VWF gene expression have led to identification of distinct regions that are necessary for activation in vascular endothelial cells of specific organs, as well as identification of a number of transactivators that participate in regulation of VWF promoter activity. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] A proximal VWF promoter region spanning sequences −487 to +247 is necessary for endothelial-specific activation but targets expression only to brain vascular endothelial cells in vivo, although mutation of an nuclear factor (NF)-I-binding site that functions as a repressor in this promoter fragment results in the promoter activation in lung and heart endothelial cells as well as brain. 24, 27, 31 Additionally, we had previously reported identification of a DNase 1 hypersensitive region in intron 51 of the VWF gene that was shown to be necessary for transcriptional activation in endothelial cells of lungs in transgenic mice. 28 Our characterization of the region that regulates the VWF transcription specifically in lungs and generation of transgenic mice that express LacZ gene under the regulation of the VWF proximal promoter and the intron 51 sequences (hypersensitive site [HSS]-VWF-LacZ and VWF-LacZ-HSS) in brain and lung endothelial cells 28 provided the opportunity to explore whether PH-generating conditions, such as hypoxia, result in modulation of the VWF transcriptional activity in lung endothelial cells and exploration of the underlying molecular mechanism.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Hypoxia Results in Upregulation of VWF Transcription and Its Redistribution From Primarily Large Vessels to Microvasculature in Lungs
To determine whether the increased levels of VWF associated with PH are regulated at transcriptional level, we chose to take advantage of our previously generated transgenic mice (HSS-VWF-LacZ and VWF-LacZ-HSS) that were used to demonstrate the lung-specific enhancer activity of the VWF intron 51 sequences (referred to as HSS). 28 In these transgenic mice, LacZ expression was regulated through the activities of the proximal VWF promoter in combination with the HSS region positioned either upstream (HSS-VWF-LacZ) or downstream (VWF-LacZ-HSS) of the proximal promoter. The presence of HSS, irrespective of its position, was shown to target the expression of LacZ gene to endothelial cells of lungs as well as brain, whereas proximal VWF promoter alone targeted LacZ expression only to brain endothelial cells. 28 Lung-specific LacZ expression was not uniform in all endothelial cells of vasculature, and this was consistent with previous reports that endogenous VWF expression is not uniformly detected in all endothelial cells of the lung vasculatures 28 and is primarily detected in larger vessels. 38 We aimed to determine whether exposure of these mice to hypoxia as a model of PH-generating condition is correlated to quantitative and qualitative changes in the activity of the VWF transcriptional regulatory sequences, and reflected in the levels and pattern of LacZ expression in these mice. Toward this goal, we chose a well-established model of hypoxia-induced PH, which results from prolonged (3-5 weeks) exposure of mice to progressively reduced oxygen levels. 39 Transgenic mice (6 mice of HSS-VWF-LacZ and 3 mice of VWF-LacZ-HSS, all aged ≈3 months) were exposed to hypoxia for 35 days, with equal numbers of age-matched littermates for each line maintained as control. The establishment of PH in hypoxiatreated mice was determined by Doppler echocardiography that was used to calculate pulmonary artery acceleration time, as previously described, [40] [41] [42] and by medial hypertrophy of vessels demonstrated in hematoxylin and eosin staining of lung sections (Figure 1 ). Pulmonary artery acceleration time is a standard clinically used parameter that correlates inversely to mean pulmonary artery pressure (ie, the lower the pulmonary artery acceleration time, the higher the mean pulmonary artery pressure). We showed a significant (P<0.05) decrease in pulmonary artery acceleration time in the hypoxic mice compared with age-matched normoxic controls. Additionally, we showed histological evidence of pulmonary vascular remodeling (medial hypertrophy) in the hypoxic mice. Taken together, these data confirm that our hypoxic exposure was effective in terms of inducing PH.
Lungs and other organs (brain, heart, liver, and kidney) were harvested from hypoxia-treated and control mice and processed for immunofluorescent analyses to detect endogenous VWF, CD31 (as a marker of microvascular and macrovascular endothelial cells), and LacZ protein expression, as well as binding to isolectin GS-IB4 from Griffonia simplicifolia (as a marker of microvascular endothelial cells). 43 Harvested organs were also processed for RNA analyses (quantitative reverse transcriptase polymerase chain reaction [RT-PCR]) to detect endogenous VWF, GAPDH, Tie-2, and transgene LacZ transcripts. Immunofluorescent analyses to detect endogenous Figure 1 . Chronic hypoxia exposure results in pulmonary vascular remodeling and reduced pulmonary artery acceleration time (PAAT) in mice. A, Hematoxylin and eosin (H&E) staining of 5-µm sections of lung from control (C) and hypoxia (H)-exposed mice shown at magnifications ×200 and inset (×1000). The inset is the higher magnification (×1000) of the area selected in rectangle, representing pulmonary arteries and demonstrating medial hypertrophy in vessels of hypoxic mice compared with control. Images are representative of 2 independent mice from control and hypoxia-treated groups. B, Doppler echocardiography was used to calculate PAAT represented in the bar graph as milliseconds in 6 control and 9 hypoxia-treated mice. A significant (*P<0.05) decrease in PAAT in the hypoxic mice compared with age-matched controls was observed.
VWF and CD31 protein levels demonstrated VWF expression in primarily large vessels of the lungs in control mice. CD31 expression marked both microvascular and macrovascular endothelial cells. In the lungs of control mice, VWF and CD31 colocalization were detected in endothelial cells in large vessels, but not those of small vessels ( Figure 2A ). In contrast, colocalization of VWF and CD31 was demonstrated in a significant number of small vessels as well as large vessels in the lungs of mice exposed to hypoxia (Figure 2A ). Isolectin GS-IB4 staining, which preferentially marks small vessels, colocalized with VWF in significantly higher number of microvessels in the lungs of hypoxic mice compared with those of control mice ( Figure 2B and 2C) . These results demonstrated a significant change in the distribution pattern of VWF with increasing number of lung microvessels exhibiting VWF expression in response to hypoxia.
Analyses of LacZ transgene expression in these mice similarly demonstrated a redistribution of LacZ transgene expression in lungs from primarily larger vessels in control to microvessels in hypoxia-treated mice ( Figure 2F ). Colocalization immunofluorescent analyses demonstrated that LacZ transgene expression colocalized to endothelial cells expressing endogenous VWF in both control and hypoxia-treated mice ( Figure 2G ). Endogenous VWF and transgene LacZ RNA analyses demonstrated that redistribution patterns of expression were accompanied by an ≈2and 1.6-fold increase in the levels of VWF and LacZ mRNA, respectively, in lungs of hypoxia-treated mice compared with control ( Figure 2D and 2E). VWF mRNA levels were normalized to Tie-2 as well as GAPDH, which demonstrated that this increase was independent of potential increase in vascular density that may result from hypoxia/PH. 3, [44] [45] [46] Together, these results demonstrate that hypoxia leads to activation of VWF transcription (endogenous and exogenously expressed VWF promoter fragment) in a subset of microvascular endothelial cells of the lung that do not normally express this gene.
Endogenous VWF mRNA Is Upregulated in Brain, Heart, and Liver, But Not Kidney, of Mice Exposed to Hypoxia
To determine whether increased VWF mRNA is a general response of all major organs to hypoxia (and developed PH), we performed similar RT-PCR analyses, as described above for lungs, in brain, kidneys, liver, and heart of hypoxic and control mice. The results demonstrated that endogenous VWF mRNA in Figure 2 . Analyses of von Willebrand factor (VWF) and LacZ expression in the lungs of control and hypoxia-exposed transgenic mice. Immunofluorescent and confocal microscopy analyses of VWF, CD31, and LacZ were performed on 5 µm optimal cutting temperature compound frozen sections of lungs from control and hypoxia-exposed VWF-LacZ-HSS transgenic mice, as previously described. 28, 31 Staining for isolectin GS-IB4 binding was performed similarly with minor modifications, as described in Methods. A, Sections were treated with preconjugated sheep anti-VWF antibody (1:250 dilution), rat anti-CD31 antibody (1:200 dilution), and donkey anti-rat Alexa 594 (1:1000 dilution) followed by confocal microscopy analyses, as previously described. 31 Tile scanning was performed to provide a composite image of a region covering ≈0.9 mm 2 of lung sections.VWF expression was detected by green, CD31 by red, and colocalization by yellow fluorescent signals (magnification ×200). B, Sections were treated with Alexa Fluor 568 conjugated isolectin GS-IB4 (1/200 dilution) and anti-VWF antibody and subjected to confocal microscopy analysis, as described for A. Panel showing isolectin GS-IB4 binding (detected as red fluorescent signal) is labeled as lectin. Colocalization of VWF and lectin is detected as yellow fluorescence in panel lectin+VWF. Yellow arrows indicate larger vessels that express VWF (green), but do not demonstrate isolectin GS-IB4 binding, and white arrows indicate smaller vessels that exhibit lectin binding. The bottom represents phase-contrast representation of the sections (magnification ×200). C, Quantification of vessels that express both VWF and lectin binding as percentage of total vessels that exhibit lectin binding in 10 fields of view (*P<0.05). D and E, RNAs (1 µg) prepared from lungs of control and hypoxia-treated transgenic mice (VWF-LacZ-HSS [3 mice] and HSS-VWF-LacZ [6 mice]) were subjected to reverse transcription and real-time polymerase chain reaction analyses to detect endogenous VWF and LacZ transgene mRNAs, as well as GAPDH and Tie-2 mRNAs. Graphs represent fold induction of the levels of VWF and LacZ normalized to Tie-2 and GAPDH in hypoxiatreated mice compared with age-matched control mice (*P<0.05). F, Sections were treated with anti-β-galactosidase antibody (goat polyclonal 1:50 dilution) and donkey anti-goat Alexa 594 (1:1000) to detect LacZ (red) in the left (magnification ×200). G, Immunofluorescent and confocal microscopy analyses to detect VWF and LacZ colocalization were performed, as described for A, except that goat anti-βgalactosidase antibody was used (as described for F) in conjunction with anti-VWF antibody. Red and green flourescent signals represent LacZ and VWF, respectively, and yellow represents colocalization (magnification ×400). All immunofluorescent results are representative of 2 to 4 independent experiments from 2 different mice for each control and hypoxia treatment.
brain, heart, and liver, but not kidneys, of hypoxic mice were significantly increased compared with control ( Figure 3A ). Because in these transgenic mice, VWF promoter directed the LacZ expression to the brain as well as lung, we performed RT-PCR analyses of the LacZ transgene in brain of hypoxic mice. The results ( Figure 3B ) demonstrated that there seemed to be some increase in LacZ transgene expression in the brain; however, the results were highly variable among the number of hypoxic animals that were analyzed and not statistically significant. Next, to determine whether hypoxia resulted in de novo activation of the transgene VWF-LacZ-HSS, we analyzed LacZ expression in heart, liver, and kidneys of control and hypoxia-treated mice. As expected, RT-PCR analyses of heart, liver, and kidneys demonstrated that there was no LacZ transgene expression in any of these organs in control mice, and there was no detectable LacZ expression in liver or kidneys of hypoxic mice. However, in heart, detectable levels of LacZ mRNA expression were observed in response to hypoxia exposure in both lines (although most consistently in VWF-LacZ-HSS) of transgenic mice ( Figure 3C ).
LacZ Transgene Expression Is Activated in the Heart of Transgenic Mice Exposed to Hypoxia
Next, we determined whether observed LacZ mRNA in heart of hypoxia-treated mice correlate with LacZ protein expression and endothelial localization of this protein. Additionally, we determined whether observed increase in endogenous VWF mRNA is accompanied with its vascular redistribution (as observed for lungs). For these analyses, we performed immunofluorescence confocal microscopy to detect endogenous VWF and LacZ in brain, heart, liver and kidneys of control and hypoxia-treated mice, as described above for lungs. The results demonstrated that there were no significant changes in cellular pattern of endogenous VWF and LacZ transgene expression in brain ( Figure 4A ). Similarly, there were no significant changes in the pattern of VWF expression in livers and kidneys and, consistent with RNA analyses, there was no detectable LacZ expression in these organs in either control or hypoxia-treated mice ( Figure 4C and 4D ). In the heart, however, consistent with the results of RNA analyses, LacZ expression, which was not detected in control mice, was clearly detectable in the heart vessels and colocalized to VWF-expressing endothelial cells ( Figure 4B ). These results demonstrate that hypoxia treatment induces activation of the VWF-HSS promoter fragment in heart endothelial cells, which in control condition do not support the activity of this promoter fragment. The results demonstrate that hypoxia neither significantly alters distribution pattern of endogenous VWF in brain, heart, liver, and kidneys, nor that of LacZ transgene in brain, liver, and kidney, whereas in heart, it leads to de novo activation of VWF-LacZ-HSS transgene expression in endothelial cells. RNAs (1 µg) prepared from various organs (brain, heart, kidneys, and liver) of transgenic mice were subjected to reverse transcription and real-time PCR analyses to detect endogenous VWF and GAPDH mRNA, as well as LacZ transgene. VWF or LacZ levels were normalized to GAPDH. There were no detectable levels of LacZ expression in livers and kidneys of either control or hypoxia-treated mice; thus, no graph presented for these analyses. LacZ expression was detected in the brain and heart of hypoxia-treated mice as shown. A, Endogenous VWF expression results represent the averages of RNA from organs of 9 control and hypoxia-treated mice (HSS-VWF-LacZ [6 mice] and VWF-LacZ-HSS [3 mice]; *P<0.05). B and C, LacZ transgene mRNA results from 3 mice of VWF-LacZ-HSS line are shown. Induction in the brain was not statistically significant, and statistical analysis for the heart was not performed because there were no detectable levels in control to perform paired t test. Optimal cutting temperature compound frozen sections of brain, heart, liver, and kidneys from control and hypoxia-exposed VWF-LacZ-HSS mice were analyzed, as described in Figure 2E for lungs. Results are representative of 2 independent experiments from 2 different mice for each control and hypoxia treatment (magnification ×400).
VWF Gene Is Upregulated in Cultured Lung Microvascular Endothelial Cells in Response to Hypoxia
Significant increase in VWF expression and its redistribution specifically in lung vasculature demonstrated that endothelial cells of this organ have a distinct response to hypoxia and conditions generated as a result of hypoxia (ie, PH). To determine whether hypoxia directly targets VWF gene regulation, and if so to explore the mechanism of its action, we used human lung microvascular endothelial cells (LMECs) in culture and performed analyses of VWF expression in these cells in response to hypoxia. Cells were maintained as control or exposed to hypoxic conditions (1% oxygen compared with normal 21%). After 1 hour of hypoxia treatment, cells were transferred to normoxic conditions, and RNA were collected at various time points (1-72 hours). RT-PCR analyses of VWF transcript demonstrated that within 1 hour (1 hour of normoxia after hypoxia treatment) increase in VWF mRNA levels was detected; however, this increase reached statistical significance (P<0.05) and was maximal at 48 hours ( Figure 5A ). As control, we also determined the levels of vascular endothelial growth factor transcript (a previously well-established target of hypoxia) 47 and demonstrated that at 48 hours after hypoxia treatment, vascular endothelial growth factor mRNA levels were also significantly increased and then declined by 72 hours ( Figure 5B ). Next, we performed Western blot analysis of the VWF protein from cellular lysate, as well as those secreted in media, and demonstrated that the increase in VWF mRNA at 48 hours was concomitant with a significant increase in intracellular and conditioned media released VWF protein levels ( Figure  5C-5E ). These results demonstrated that hypoxia directly targets regulation of VWF and results in its increased production both at protein and RNA levels.
Transcription Factors Nuclear Factor-I and YY1 Participate in Upregulation of VWF Gene in Response to Hypoxia
Hypoxia-inducible factor-1 transcription factors are wellknown regulators of gene expression in response to hypoxia and, although we cannot rule out their participation in regulation of VWF gene in response to hypoxia, our initial analyses of regulatory DNA sequences of the VWF gene did not reveal a hypoxia responsive element. However, analyses of VWF gene expression in vitro and in vivo previously demonstrated that several transacting factors positively and negatively participate in its transcriptional regulation. Specifically, we demonstrated the transcription factor YY1 association with the VWF intron 51 sequences that target lung-specific activity of the VWF promoter. 28 Also recently, we have demonstrated that the nuclear factor (NF)-IB transcription factor functions as repressor of VWF promoter in lung and heart endothelial cells in vivo. 31 Our observation that hypoxia exposure resulted in VWF transgene (VWF-LacZ-HSS) de novo activation in heart vascular endothelial cells ( Figure 4B ), as well as LMECs, raised the possibility that NF-IB levels and activity may be targets of hypoxia. Additionally, specific association of YY1 with lungspecific enhancer sequences (HSS) of the VWF gene suggested that possible modification of YY1 activity may also contribute to VWF transcription regulation in response to hypoxia specifically in the lungs. To test the above hypotheses, we first determined whether levels of NF-IB and YY1 are modified in LMECs in response to hypoxia. RNA prepared from control and hypoxia-exposed LMECs at 24, 48, and 72 hours were analyzed to detect NF-IB and YY1 mRNA by RT-PCR, as described above for VWF mRNA. The results demonstrated that both NF-IB and YY1 mRNA levels were increased in response to hypoxia maximally at 48 hours; however, the level of increase in YY1 was more extensive, and it was maintained at longer time point ( Figure 6A and 6B ). Next, we determined Figure 5 . Analyses of von Willebrand factor (VWF) expression in control and hypoxia-treated lung microvascular endothelial cells (LMECs) in culture. LMECs were maintained as control or exposed to hypoxia (1% oxygen for 1 hour), followed by 24, 48, and 72 hours of normoxia. (A and B) RNA (150 ng) were collected and subjected to real-time polymerase chain reaction analyses to detect GAPDH and (A) endogenous VWF mRNA as well as (B) vascular endothelial growth factor (VEGF), as described in Methods. VWF and VEGF levels were normalized to GAPDH and demonstrated significant (*P<0.05) increase at 48 hours after hypoxia induction. C, Total protein (50 µg) collected from cells at 48-hour time point (1 hour hypoxia followed by 48 hours normoxia) and corresponding control were exposed to Western blot analyses to detect VWF and tubulin. D, Densitometry tracing of the VWF signal compared with tubulin from 3 independent blots indicated significant (*P<0.05) increase in VWF signal intensity in hypoxia compared with control. E, Conditioned media (30 µL) collected from control and hypoxia-treated cells at 48-hour time point (1 hour hypoxia followed by 48 hours normoxia) were directly used in Western blot analyses to detect secreted VWF, as described for C. VWF signal detected at >250 kD compared with Western blot analyses of lysate may be indicative of multimerized VWF that is secreted from the cells into the cultured media.
whether this increase in mRNA correlates to an increase in NF-IB and YY1 proteins by Western blot analyses of total, as well as nuclear protein preparation of control and hypoxiatreated LMECs. The results demonstrated that NF-IB protein levels were not significantly altered in either total lysate or nuclear fractions in response to hypoxia, whereas a significant increase in nuclear fraction, but not total lysate levels of YY1 protein were detected ( Figure 6C ).
To determine whether functional activities of NF-IB and YY1 were altered in response to hypoxia, we next determined the levels of associations of these transacting factors with their cognate binding sites on the VWF gene regulatory elements. Chromatin immunoprecipitation assays were performed for these analyses, and the results demonstrated that association of NF-IB with the VWF promoter was significantly reduced, whereas association of YY1 with its cognate binding site on intron 51 HSS sequences was significantly increased ( Figure 6D ).
To directly determine the role of YY1 in hypoxia induction of the VWF, we transfected LMECs with small interfering RNA (siRNA) directed against YY1 transcript and determined the effect of YY1 knockdown on VWF expression in control and hypoxia-treated cells. For these analyses, LMECs were transfected with YY1-specific or a nonsilencing siRNA, as described in Methods, and 48 hours after transfection cells were maintained as control or exposed to hypoxia, as described above. Whole lysate proteins were prepared 48 hours after hypoxia treatment and subjected to Western blot analyses to determine the levels of YY1 and VWF. The results demonstrated that YY1-specific siRNA treatment significantly reduced the levels of YY1, and that this was accompanied by a significant decrease in the levels of VWF in both control and hypoxia-treated LMECs ( Figure 6E ). Chromatin immunoprecipitation were also performed and demonstrated that YY1-specific siRNA treatment abolished hypoxia-induced increase in YY1 association with its target binding site on VWF chromatin ( Figure 6F ). These results demonstrated that YY1 participates in basal level as well as hypoxia-induced transcription of VWF in LMECs.
Because analyses of YY1 levels demonstrated that there was a significant increase in nuclear YY1 levels in response to hypoxia, we next determined whether this increase is also observed in vivo in the lung endothelial cells of hypoxia-treated mice as well as hypoxia-exposed cultured LMECs. For these analyses, we chose to perform confocal immunofluorescence analyses of YY1 on lung sections of control and hypoxia-treated mice. To correlate this with VWF expression, we used VWF staining for colocalization. We first performed these analyses on cultured cells and demonstrated that consistent with the results of Western blot analyses, there was a significant increase in nuclear YY1 concomitant with increased levels of VWF detectable by immunofluorescent analyses (Figure 7A ). Next, Figure 6 . Continued (*P<0.05). G, A representative gel analyses of real-time PCR product of chromatin immunoprecipitation assay demonstrating lack of PCR product in negative control (water only, labeled as -) and significantly lower levels of detected PCR product in chromatin immunoprecipitated with nonspecific IgG antibody, whereas specific PCR products were detected from input chromatin (positive control labeled as In) and those immunoprecipitated with YY1 antibody from control (C/YY1) and hypoxia (H/YY1)-treated cells. Figure 6 . Analyses of von Willebrand factor (VWF), nuclear factor (NF)-IB, YY1 expression, and interaction with the VWF chromatin in control and hypoxia-treated lung microvascular endothelial cells (LMECs) in absence and presence of YY1-specific small interfering RNA (siRNA). LMECs were maintained as control or exposed to hypoxia, as described in Figure 5. A and B , Reverse transcriptase polymerase chain reaction (PCR) analyses on collected RNA were performed using specific primers ( Table I in the online-only Data Supplement) to detect nuclear factor (NF)-IB, YY1 mRNA, and GAPDH at specified time points. Time points indicating significant (*P<0.05) increase are marked (*). C, Nuclear and total lysates (50 µg for total and 100 µg for nuclear component) collected from cells at 48-hour time point (1 hour hypoxia followed by 48 hours normoxia) and corresponding control were exposed to Western blot analyses to detect NF-IB, YY1, tubulin, and lamin. Lack of tubulin detection in the nuclear extract is indicative of lack of cytoplasmic contamination of nuclear extract preparation. Lamin was used as loading control for nuclear extracts. D, Chromatin immunoprecipitations were performed on control and hypoxia-treated cells (48hour time point) using antibodies specific to NF-IB, YY1, or IgG (as negative control). Immunoprecipitated chromatin were subjected to quantitative real-time PCR analyses to detect amplified VWF DNA sequences that corresponded to NF-I-binding site or YY1binding sequences in intron 51, as previously described. 31 The primer sequences are presented in Table I in the online-only Data Supplement. Results represent fold increase in amplified DNA detected by NF-IB or YY1 immunoprecipitation compared with IgG from 4 independent experiments (*P<0.05). E and F, LMECs were transfected with either siRNA specific for YY1 or nonspecific (NS) siRNA, as described in Methods. Cells were then exposed to hypoxia or normoxia for 1 hour and, after 48 hours, cells were harvested for protein analyses and chromatin immunoprecipitation. E, A representative blot of 6 independent experiments, indicating efficient YY1 knockdown by siRNA transfection of cells and also reduction of VWF expression in YY1 knockdown cells. F, Chromatin immunoprecipitation of cells using antibodies specific to YY1 or IgG. Purified chromatin was amplified with real time-PCR using specific primers to detect sequences corresponding to YY1binding site on the VWF gene, as described in Methods. Results represent fold change in amplified DNA detected by YY1 immunoprecipitation compared with IgG from 3 independent experiments similar analyses were performed on optimal cutting temperature compound frozen lung section of hypoxia-exposed and control mice, and the results demonstrated that there was a significant increase of YY1 in the nucleus of VWF-expressing endothelial cells in lungs of hypoxia-treated mice compared with control ( Figure 7B ). Together, these results demonstrate that increased YY1 in the nucleus is concomitant with increased binding of YY1 with the VWF promoter, and this process combined with decreased association of NF-IB repressor with the VWF promoter correlates with increased VWF transcriptional activity.
Hypoxia Results in Increased Platelet Adhesion to Monolayer of Cultured LMECs
To determine the functional effect of increased VWF expression in response to hypoxia, we performed a platelet-binding assay (laminar flow adhesion assay) that would demonstrate whether increased levels of VWF correlate with increased plateletbinding activities. For this assay, control and hypoxia-treated LMEC monolayer grown on cover slips were exposed to shear stress, whereas isolated human platelets were perfused over the monolayer, as described in Methods. Platelet chains were observed by an inverted phase-contrast microscope ( Figure 8A) , and the number of platelet chains forming after 4 minutes of exposure to shear stress was determined in 5 different fields of view ( Figure 8D ). Cover slips containing LMEC-platelet coculture were then gently removed from shear stress, fixed with 4% paraformaldehyde and subjected to immunofluorescent analyses using cd42b antibody conjugated to phycoerythrin to detect platelets ( Figure 8B ), or subjected to confocal immunofluorescent analyses using cd42b and VWFspecific antibodies to detect colocalization of platelets and VWF ( Figure 8E ). The results of phase-contrast microscopy analyses demonstrated that there was a significant increase in the number of platelet chains formed over the monolayer of hypoxia-treated LMECs compared with control ( Figure  8D compare no treatment in control and hypoxia). We also observed that on removal of shear stress the platelet chains dissociated rapidly, but the dissociation occurred at a slower rate in hypoxia-treated LMECs compared with control. This observation was supported by immunofluorescence analyses of LMEC-platelet coculture demonstrating a significant number of platelet chains on hypoxia-treated LMECs, whereas the number of platelet chains on control LMECs were few or nondetectable ( Figure 8B ). These results demonstrate that increased VWF expression in response to hypoxia leads to increased platelet adhesion and formation of platelet chains with increased stability. To determine whether this increased platelet chain formation was dependent on VWF and also to determine whether YY1 activity contributed to this process, Figure 7 . Immunofluorescent analyses of YY1 expression in human lung microvascular endothelial cells (LMECs) in vitro and in vivo in response to hypoxia. A, Cultured LMECs maintained as control or exposed to hypoxia (1 hour hypoxia and 48 hours normoxia), and (B) Optimal cutting temperature compound frozen sections of lungs from control and hypoxia-treated mice were subjected to immunofluorescent analyses and confocal microscopy to detect YY1 (red) and von Willebrand factor (VWF; green), as described in Methods and Figure 1E . Nuclei were stained with 4',6-diamidino-2-phenylindole (blue). Results are representative of 2 independent experiments for cultured LMECs and 2 mice for each control and hypoxia treatment (magnification ×600).
Figure 8.
Endothelial exposure to hypoxia increases platelet binding to endothelial monolayer under shear stress. A and B, Lung microvascular endothelial cells (LMECs) were incubated in hypoxic conditions, as described in Figure 5 . The endothelial monolayer was exposed to 1 dyne/cm 2 shear stress for ≈30 seconds, and then freshly isolated human platelets were perfused over the monolayer for 10 minutes. A, Bright-field zoomed area of the movie acquired at 10 minutes in both control and hypoxia-induced monolayer. B, Immunofluorescent staining of the endothelial cells (nucleus stained with 4',6-diamidino-2-phenylindole: blue) and platelet (cd42b antibody: red) interactions, as described in Methods. C-D, LMECs were untreated (NT) or transfected with nonspecific (NS) small interfering RNA (siRNA), siRNA specific for YY1 (SiYY1) or siRNA specific for von Willebrand factor (SiVWF), as described in Methods. Cells were then exposed to hypoxia or normoxia for 1 hour and, after 48 hours, cells were used in platelet-binding assay, as described above, and used in Western blot analyses to demonstrate efficacy of VWF siRNA treatment. C, Representative blot of 2 independent experiments, indicating efficient VWF knockdown by SiVWF transfection of cells. D, Quantification of number of platelet chains observed in 5 different fields of view after 4 minutes. E, Immunofluorescent staining and confocal microscopy analyses of the VWF (green) and platelet (cd42b antibody: red) interactions, as described in Methods (magnifications for all immunostainings are ×400).
we performed similar experiments with cells that were treated with siRNA that specifically targets VWF or YY1. As previously shown in Figure 6E , we demonstrated that siRNA targeting of YY1 significantly reduced VWF as well as YY1 levels in the cells. Efficacy of the siRNA targeting the VWF was demonstrated by Western blot analyses of LMECs that were transfected with VWF siRNA compared with a nonspecific siRNA ( Figure 8C ). The results of plateletbinding assays demonstrated that both VWF siRNA and YY1-specific siRNAs compared with nonspecific siRNA significantly reduced the number of platelet chains binding to LMECs in hypoxia-treated cells ( Figure 8D ). Nonspecific siRNA treatment compared with no treatment also seemed to modestly but significantly reduce the platelet chain formation in hypoxia-treated cells, and more significantly in control cells. This may be attributable to the process of transfection that may induce the release of VWF, thus reducing the overall levels of VWF in cells before hypoxia treatment and binding assays. Nevertheless in comparing control and hypoxia-treated cells, both no treatment and nonspecific siRNA treatment demonstrated significantly higher platelet chain formation on hypoxia-treated cells, whereas VWF siRNA and YY1specific siRNAs treatment abolished this increased platelet binding to similar levels observed with control cells ( Figure  8D) . Confocal immunofluorescent analyses also demonstrated formation and colocalization of platelet chains (labeled by red fluorescence of cd42b conjugated antibody and shown as yellow when colocalizing with VWF) on extended VWF molecules (shown by green florescence) in hypoxia-exposed cells both in no treatment and nonspecific-treated cells. The extended VWF molecule and colocalizing platelets were not detected in VWF siRNA and YY1-specific siRNAs treated cells in either hypoxia or control cells ( Figure 8E ).
Discussion
Transgenic mice expressing LacZ transgene under the regulation of brain-and lung-specific transcriptional regulatory elements of VWF gene were used to explore the mechanism(s) of VWF upregulation in a mouse model of PH that involves hypoxia exposure. 39 Immunofluorescent analyses of endogenous VWF and LacZ transgene expression in hypoxia-treated mice compared with control demonstrated that whereas in control mice expressions were mainly restricted to larger vessels, in hypoxia-treated mice expressions were redistributed to include significant regions of microvasculature. RNA analyses demonstrated a concomitant increase in the levels of endogenous VWF and LacZ transgene transcripts in lungs of hypoxia-exposed mice compared with control mice. These results demonstrated that hypoxia alters transcriptional activity of the VWF promoter in lung endothelial cells in a manner that exhibits upregulation, as well as de novo activation in endothelial cells that normally do not express VWF. Our immunofluorescent analyses of the endogenous VWF and LacZ transgene expression in the brain of control and hypoxia-treated mice did not demonstrate a significant alteration in the pattern of expression. However, RNA analyses demonstrated a significant increase in the levels of endogenous VWF mRNA. Similarly, a significant increase in the levels of endogenous VWF mRNA in heart and liver, but not kidneys, of hypoxia-treated mice compared with control was demonstrated. These observations suggest that whereas in lung de novo activation of the VWF transcription in microvascular endothelial cells is detected, increased transcriptional activity of VWF in endothelial cells that support the basal expression of VWF in lung, brain, heart, and liver is also observed, thus, suggesting that either a common mechanism or 2 independent processes may be invoked by hypoxia treatment/PH leading to increased and de novo activation of the VWF transcription. The observed increase in VWF mRNA in multiple organs, but not in kidney, may be a reflection of differential sensitivities of endothelial cells of these organs to hypoxia. Analyses of VWF transcriptional regulation in cultured LMECs demonstrated that hypoxia treatment resulted in an ≈3-fold increase in the levels of VWF mRNA, accompanied by increased levels of VWF protein, leading to increased chains of platelets that are formed in association with the LMEC monolayer. These increased levels of platelet chain formation were abolished by treatment of cells with siRNA that specifically targeted the VWF expression, thus demonstrating that the increased levels of VWF functionally contribute to increased platelet adhesion to LMECs and as such may contribute to thrombus formation in vivo.
An intriguing observation in the analyses of LacZ transgene expression was detection of transgene in the heart endothelial cells of hypoxia-treated mice. Lack of LacZ transgene expression in all organs tested, except lung and brain, in control mice was consistent with previous analyses of these transgenic mice and consistent with lung and brain endothelial activation pattern of these VWF regulatory elements (−487 to +247 combined with intron 51 sequences). However, the activation of the transgene in response to hypoxia in heart endothelial cells suggested that the molecular mechanism(s) leading to VWF activation in response to hypoxia may include alterations in functions of transacting factors that normally participate as repressors of the VWF promoter activity. We have recently reported that 2 repressors, NF-I and NF-Y, participate in organ-specific activity of the VWF promoter. 31 Specifically mutation of NF-I-binding site was shown to activate VWF promoter sequences (−487 to +247) in lung and heart endothelial cells, in addition to brain; whereas the wild-type promoter was activated only in brain endothelial cells. 31 Additionally, we demonstrated that among 4 NF-I isoforms (A, B, C, and X), NF-IB was predominantly detected in lung and heart endothelial cell nuclei. 31 Based on these results, we hypothesized that NF-IB may be a target of hypoxia, and alteration in its level and function may contribute to transgene activation in endothelial cells of the heart as well as LMECs. However, lung-specific activity of the VWF promoter sequences were also shown to be regulated through sequences in intron 51 region of the VWF gene. We have shown that YY1 interacts with these sequences and contribute to its regulatory activities. Additionally, through a process involving chromatin looping, YY1-binding intron 51 sequences are brought to close proximity of the proximal NF-IB-binding VWF region, potentially allowing for YY1 to influence NF-IB function and alleviate its repressive effect. 31 Thus, we also hypothesized that YY1 activity may be a target of hypoxia, and alteration of its levels or function may also contribute to hypoxia-induced upregulation of VWF, specifically in lung endothelial cells. Thus, we explored the roles of these 2 transacting factors, NF-IB and YY1, in hypoxia induction of VWF.
Our analyses demonstrated that hypoxia-induced VWF upregulation was not accompanied by any changes in the levels or distribution of NF-IB; however, association of NF-IB with the VWF promoter sequences was significantly decreased. This result is consistent with the hypothesis that alleviation of NF-IB repressive function on the VWF promoter may contribute to VWF transcriptional upregulation in response to hypoxia. RNA and protein analyses of YY1 demonstrated a significant increase in the levels of YY1 mRNA, concomitant with a significant increase in the nuclear levels of YY1 protein in hypoxia-treated cells compared with control. Immunofluorescent analyses also demonstrated that both in vitro and in vivo levels of YY1 are significantly upregulated in the nuclei of hypoxia-treated cultured LMECs, as well as in LMECs of hypoxia-treated mice. In addition, chromatin immunoprecipitation analyses demonstrated that YY1 interaction with its cognate binding site on the intron 51 HSS sequences of VWF gene were significantly enhanced in response to hypoxia. Furthermore, we demonstrated that the knockdown of YY1 by siRNA treatment significantly reduced the basal and hypoxiainduced levels of VWF and eliminated increased platelet chain formation on the surface of cultured LMECs. These results demonstrate that YY1 regulation is a target of hypoxia and positively contributes to upregulation of VWF. Additionally, the significant decrease in basal level of VWF in YY1-specific siRNA-treated LMECs is consistent with our previous results, demonstrating the role of YY1-interacting intron 51 sequences in lung-specific activation of the VWF promoter.
NF-IB and YY1 may independently contribute to VWF upregulation and may contribute differentially to transcriptional upregulation (observed in most organs) versus de novo activation (observed in LMECs). Alternatively, the close proximity of these 2 negative and positive regulators of the VWF promoter through chromatin looping may influence binding activity of one by another. Specifically, enhanced binding of YY1 in response to hypoxia may lead to decreased binding of NF-IB, resulting in increased and de novo activation of VWF transcription in LMECs. This is also consistent with previous reports that demonstrate YY1 can influence activities of other transacting factors, including P53 and hypoxia-inducible factor-α. 48, 49 YY1 is accumulated in cytoplasm, but phosphorylated YY1 is activated and moves to the nucleus, where it can interact with various molecules, modify them, and ultimately alter their functions. 50 In conclusion, our data here are consistent with a hypothesis that PH and conditions leading to this process, including hypoxia, are associated with a phenotypic shift of endothelial cells from anticoagulant to procoagulant activity. We additionally propose that this process of phenotypic shift includes modification of specific transacting factors, including NF-IB and YY1, which target regulation of VWF and potentially other endothelial-specific genes. 
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